News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
694,162 Results
Type
Article (40044)
Company Profile (331)
Press Release (653787)
Section
Business (206983)
Career Advice (2051)
Deals (35902)
Drug Delivery (87)
Drug Development (82163)
Employer Resources (172)
FDA (16166)
Job Trends (15125)
News (349836)
Policy (32813)
Tag
Academia (2556)
Alliances (49975)
Alzheimer's disease (1241)
Approvals (16086)
Artificial intelligence (125)
Bankruptcy (355)
Best Places to Work (11602)
Biotechnology (235)
Breast cancer (110)
Cancer (957)
Cardiovascular disease (83)
Career advice (1708)
Cell therapy (212)
Clinical research (65038)
Collaboration (341)
Compensation (174)
COVID-19 (2547)
C-suite (83)
Data (914)
Diabetes (138)
Diagnostics (6130)
Earnings (85383)
Employer resources (150)
Events (111538)
Executive appointments (260)
FDA (16629)
Funding (300)
Gene therapy (156)
GLP-1 (589)
Government (4362)
Healthcare (18751)
Infectious disease (2625)
Inflammatory bowel disease (104)
Interviews (325)
IPO (16535)
Job creations (3835)
Job search strategy (1462)
Layoffs (424)
Legal (7914)
Lung cancer (156)
Manufacturing (161)
Medical device (13182)
Medtech (13187)
Mergers & acquisitions (19399)
Metabolic disorders (378)
Neuroscience (1488)
NextGen Class of 2024 (6562)
Non-profit (4483)
Northern California (1269)
Obesity (222)
Opinion (193)
Patents (96)
People (57022)
Phase I (20227)
Phase II (28683)
Phase III (21307)
Pipeline (255)
Postmarket research (2565)
Preclinical (8604)
Radiopharmaceuticals (244)
Rare diseases (188)
Real estate (6067)
Regulatory (21743)
Research institute (2333)
Resumes & cover letters (354)
Southern California (1136)
Startups (3650)
United States (12251)
Vaccines (552)
Weight loss (169)
Date
Today (226)
Last 7 days (929)
Last 30 days (3196)
Last 365 days (36119)
2024 (31411)
2023 (40681)
2022 (51812)
2021 (56360)
2020 (54582)
2019 (47021)
2018 (35413)
2017 (32716)
2016 (32119)
2015 (38168)
2014 (32052)
2013 (26961)
2012 (29102)
2011 (29750)
2010 (27754)
Location
Africa (737)
Arizona (189)
Asia (39000)
Australia (6184)
California (2880)
Canada (1200)
China (222)
Colorado (128)
Connecticut (130)
Europe (82607)
Florida (412)
Georgia (102)
Illinois (316)
Indiana (186)
Kansas (95)
Maryland (548)
Massachusetts (2377)
Michigan (144)
Minnesota (256)
New Jersey (859)
New York (869)
North Carolina (719)
Northern California (1269)
Ohio (130)
Pennsylvania (776)
South America (1116)
Southern California (1136)
Texas (407)
Utah (82)
Washington State (334)
694,162 Results for "shanghai zhimeng biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA - A Potassium Ion Channel Opener for Amyotrophic Lateral Sclerosis
Shanghai Zhimeng Biopharma, Inc. (“Zhimeng”), announced that one of its innovative small-molecule KCNQ2/3 selective opener compounds (CB03), developed for the treatment of amyotrophic lateral sclerosis (ALS), received orphan drug designation (ODD) from US FDA.
October 20, 2023
·
3 min read
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the
BioSpace
list of 12 top companies hiring life sciences professionals like you.
November 7, 2024
·
1 min read
·
Angela Gabriel
Press Releases
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
November 4, 2024
·
1 min read
Artificial Intelligence
AI Is Accelerating Biopharma Innovation But Not Erasing a Human’s Touch
Artificial intelligence won’t replace people in biopharma, but it is infiltrating every step of drug development, including in some ways that aren’t so obvious.
October 16, 2024
·
5 min read
·
Annalee Armstrong
Business
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
VGXI, Inc. has entered into a strategic partnership with Sutro Biopharma, Inc. to support clinical production of luveltamab tazevibulin, abbreviated as “luvelta”, a novel Folate Receptor-α -targeting antibody-drug conjugate with the potential to address the unmet need in several FRα-expressing cancers.
June 3, 2024
·
4 min read
Business
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024.
May 13, 2024
·
17 min read
Drug Development
Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06
Shanghai Zhimeng Biopharma, Inc. (“Zhimeng”), announced dosing of the first participant in the US Phase I study of its novel TLR8 agonist (CB06), which is being developed for the treatment of chronic hepatitis B virus infection.
March 31, 2022
·
3 min read
Biotech Beach
Navigate BioPharma Services, Inc. Launch Assay for Precise Measurement of Radioligand Therapy Response in Tumors
Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, launch a new assay for quantifying pharmacodynamic markers of radioligand therapies in tumors.
May 31, 2024
·
3 min read
FDA
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of HERCESSI™ (trastuzumab-strf)
Accord BioPharma , Inc. announced that the U.S. Food and Drug Administration (FDA) has approved HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), to treat HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma.
April 29, 2024
·
11 min read
Biotech Beach
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024
Regen BioPharma, Inc., a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on May 9, 2024.
May 7, 2024
·
3 min read
1 of 69,417
Next
